
PALE-40 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
PALE-40
Pantoprazole Sodium 40mg
PALE-40 is an advanced gastro-protective formulation developed for the rapid healing of mucosal erosion, acid peptic disorders, and gastroesophageal reflux disease (GERD).
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Forms a polyanionic protective barrier coating over inflamed gastric ulcers, preventing enzymatic acid degradation while facilitating tissue re-epithelialization.
Administer on an empty stomach 1 hour before principal meals, or as posology prescribed by the gastroenterologist.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store between 2°C to 8°C or below 25°C as indicated on label. Protect from light.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
PALE-40 features Pantoprazole Sodium 40mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Apply for Exclusive Marketing Rights of PALE-40
Check vacant territory availability in your state or district. Enjoy full marketing kit support, visual aids, and guaranteed zero competitor supply.
Questions Regarding PALE-40
What is the therapeutic indication and composition of PALE-40?
PALE-40 contains Pantoprazole Sodium 40mg indicated for Peptic Ulcer Disease as formulated by Sygnus Biotech.
What packaging presentations are available for PALE-40?
PALE-40 is supplied in tamper-evident Single Dose Sterile Vial with Ampoule & WFI, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for PALE-40?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for PALE-40 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
PALE-40 is categorized as Schedule H1 Prescription Drug with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Injection
View all Injection →
SBCEF-S 375MG
Ceftriaxone Sodium 250mg + Sulbactam 125mg Injection

SBCEF-TZ 1.125GM
Ceftriaxone Sodium 1000mg + Tazobactam 125mg


